Use of epileptic animals for adverse effect testing

Epilepsy Research

Volumn 50, Issue 1-2, 2002, Pages 55-65

  Klitgaard, Henrik ^a   Matagne, Alain ^a   Lamberty, Yves ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Adverse effects; Antiepileptic drugs; Genetic animals; Kindling; Levetiracetam

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 AMINO 5 PHOSPHONOVALERIC ACID; 3 [1 [3 [(CYCLOHEXYLMETHYL)HYDROXYPHOSPHINYL] 2 HYDROXYPROPYLAMINO]ETHYL]BENZOIC ACID; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CGP 61334; CLONAZEPAM; DEXTROMETHORPHAN; DIAZEPAM; DIZOCILPINE; ETIRACETAM; IFENPRODIL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTETRAZOLE; PHENOBARBITAL; PILOCARPINE; SEROTONIN; VALPROIC ACID;

AMYGDALOID NUCLEUS; AUDIOGENIC SEIZURE; BRAIN DYSFUNCTION; COGNITION; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; EPILEPSY; KINDLING; MOTOR PERFORMANCE; NONHUMAN; PHOTOSENSITIVITY; PREDICTION; PRIORITY JOURNAL; RODENT; VALIDATION PROCESS;

ANIMALS; ANTICONVULSANTS; COGNITION; DISEASE MODELS, ANIMAL; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KINDLING, NEUROLOGIC; MICE; RATS; RECEPTORS, GABA-B; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0036348415     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00068-2     Document Type: Article

References (36)

1. Flunarizine - Its effect on pentylenetetrazol-kindled seizures and on related cognitive disturbances
2. Antiepileptic drugs - Their effects on kindled seizures and kindling-induced learning impairments
3. Anticonvulsant activity of two orally active competitive N-methyl-D-aspartate antagonists, CGP 37849 and CGP 39551, against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio
4. Anxiogenic-like consequences in animal models of complex partial seizures
5. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: Comparison with CPPene
6. Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP 37849 and CGP 39551 in genetically epilepsy-prone rats
7. Cognitive and behavioral effects of antiepileptic drugs
8. Effects of GABAB receptor antagonists on learning and memory retention in a rat model of absence epilepsy
9. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus
10. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs
11. Recent advances in the phencyclidine model of schizophrenia
12. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
13. Consequences of pentylenetetrazole kindling on spatial memory and emotional responding in the rat
14. Cognitive performance is unaltered by levetiracetam (ucb L059) in the pilocarpine model of chronic epilepsy
15. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats
16. The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice
17. Noncompetitive excitatory amino acid receptor antagonists
18. High doses of memantine (1-amino-3, 5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats
19. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine
20. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: Attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptors
21. Responses to NMDA receptor antagonists altered by epileptogenesis
22. Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats
23. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation?
24. Genetic absence epilepsy in rats from Strasbourg - A review
25. Validation of corneally kindled mice: A sensitive screening model for partial epilepsy in man
26. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters
27. Chronic electrode implantation entails epileptiform field potential in rat hippocampal slices, similarly to amygdala kindling
28. New antiepileptic agents: Strategies for drugs development
29. Corneal kindling in mice: Behavioral and pharmacological differences to conventional kindling
30. Hippocampal extracellular amino acids and EEG spectral analysis in a genetic rat model of absence epilepsy
31. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent orally-active anticonvulsants in rodents
32. The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy
33. The behavioral effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor
34. Epilepsy and behaviour
35. Effects of nootropic drugs in scopolamine-induced amnesia model in mice
36. Electrical but not chemical kindling increases sensitivity to some phencyclidine-like behavioral effects induced by the competitive NMDA receptor antagonist D-CPPene in rats